MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/2643-3230.bcd-25-0345

Медицинская библиотека · Blood cancer discovery · 2026

Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Swaminathan Mahesh, Ferrajoli Alessandra, Thompson Philip A, Burger Jan, Borthakur Gautam, Takahashi Koichi, Estrov Zeev, Bharathi Vanthana, Bataller Alex, Kadia Tapan M, Pemmaraju Naveen, Daver Naval, Jabbour Elias, Bose Prithviraj, Kanagal-Shamanna Rashmi, Patel Keyur P, Wang Sa A, Garg Naveen, Hwang Hyunsoo, Wang Xuemei, Qiao Wei, Xu Xun, Cruz Nichole, Ayala Ana, Pierce Sherry, Plunkett William, Sampath Deepa, Kantarjian Hagop M, Keating Michael J, Gandhi Varsha, Wierda William G, Jain Nitin

СтатьяКлиническое исследование II фазыПеревод в очереди

Аннотация

UNLABELLED: We explored the efficacy of the combination of ibrutinib + venetoclax in patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL). This phase II study enrolled 80 patients between July 2016 and September 2018. Patients received ibrutinib for the first 3 cycles, followed by ibrutinib + venetoclax for 24 cycles. Of the 79 treated patients, the median age was 61 years (IQR, 56-69); 65 (65/76, 86%) had unmutated IGHV and 29 (37%) had either del(17p) or a TP53 mutation. The median number of prior treatments was 1 (range, 1-3). The primary endpoint, best complete remission (CR) and CR with incomplete count recovery (CRi), was 67%, with a bone marrow undetectable measurable residual disease [10-4 sensitivity (U-MRD4)] rate of 61%. At 95.5 months of median follow-up, the estimated 7-year progression-free survival rate was 63.3%. Grade ≥3 neutropenia and thrombocytopenia occurred in 38% and 13% of patients, respectively. The 24-cycle ibrutinib + venetoclax combination led to high rates of CR/CRi and bone marrow U-MRD4 in patients with R/R CLL.

SIGNIFICANCE: The 24-cycle ibrutinib + venetoclax combination led to high rates of CR/CRi and bone marrow U-MRD4 in patients with R/R CLL. Responses were durable, including in patients with high-risk genomics.

Для цитирования: Swaminathan Mahesh, Ferrajoli Alessandra, Thompson Philip A, Burger Jan, Borthakur Gautam, Takahashi Koichi, Estrov Zeev, Bharathi Vanthana, Bataller Alex, Kadia Tapan M, Pemmaraju Naveen, Daver Naval, Jabbour Elias, Bose Prithviraj, Kanagal-Shamanna Rashmi, Patel Keyur P, Wang Sa A, Garg Naveen, Hwang Hyunsoo, Wang Xuemei, Qiao Wei, Xu Xun, Cruz Nichole, Ayala Ana, Pierce Sherry, Plunkett William, Sampath Deepa, Kantarjian Hagop M, Keating Michael J, Gandhi Varsha, Wierda William G, Jain Nitin. Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.. Blood cancer discovery. 2026. DOI: 10.1158/2643-3230.bcd-25-0345.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.